TapewireFind a company

person · Reporting owner

Aebersold Sarah

Disclosed activity across 1 company

Tapewire entity
56695
SEC CIK
0001837756

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

No relationships currently tracked through insider filings.

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

No balances currently tracked through insider filings.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

BIOLIFE SOLUTIONS INC

Report date March 19, 2026 · Filed March 23, 2026

Section 16 reporting ended · disclosed 2026-03-23. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect92,429 Reported balance After 2026-03-19 transaction · row 1
1 source row

Row 1 · 2026-03-19 · Tax withholding · Disposed 931 · Balance 92,429

F1: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 14, 2023 Filed Aug 16, 2023 20:46 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 104 $12.38 $1,287.52
Disclosure

SEC source: 0001628280-23-029681 · wk-form4_1692218782.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,879

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
July 24, 2023 Filed Jul 26, 2023 22:08 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 462 $19.50 $9,009.00
Disclosure

SEC source: 0001628280-23-025783 · wk-form4_1690409329.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,983

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 07-17-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
May 31, 2023 Filed Jun 3, 2023 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 337 $23.21 $7,821.77
Disclosure

SEC source: 0001437749-23-016543 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,445

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
May 15, 2023 Filed May 18, 2023 01:52 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 72 $18.71 $1,347.12
Disclosure

SEC source: 0001437749-23-015003 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,782

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
April 19, 2023 Filed Apr 21, 2023 23:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 292 $19.33 $5,644.36
Disclosure

SEC source: 0001437749-23-010841 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,059

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

F2 · kind: Adoption date of referenced 10b5-1(c) plan is: 7/17/2020

Read SEC document
April 06, 2023 Filed Apr 10, 2023 23:01 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 739 $20.03 $14,802.17
Disclosure

SEC source: 0001437749-23-009874 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,351

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
April 06, 2023 Filed May 17, 2023 01:47 UTC Amendment BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 739 $20.03 $14,802.17
Disclosure

SEC source: 0001437749-23-014860 · rdgdoc.xml · nonDerivative · entry 2

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,146

F2 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

F3 · balance_after: This reflects the total amount beneficially owned by the reporting person as of April 10, 2023. Subsequent Form 4's filed by the reporting person after April 10, 2023 do not currently reflect the vesting of the 2,795 shares.

Read SEC document
March 31, 2023 Filed May 17, 2023 01:47 UTC Amendment BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionRestricted Stock Award · Derivative 2,795 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001437749-23-014860 · rdgdoc.xml · derivative · entry 3

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,795 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F1 · derivative.expiration_date: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

Read SEC document
March 31, 2023 Filed May 17, 2023 01:47 UTC Amendment BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionCommon Stock 2,795 Not disclosed Not disclosed
Disclosure

SEC source: 0001437749-23-014860 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,885

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F1 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

Read SEC document
March 01, 2023 Filed Mar 4, 2023 00:01 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 1,022 $22.75 $23,250.50
Disclosure

SEC source: 0001437749-23-005440 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,090

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
February 09, 2023 Filed Feb 14, 2023 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 55 $24.60 $1,353.00
Disclosure

SEC source: 0001437749-23-003204 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,112

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
January 19, 2023 Filed Jan 21, 2023 00:24 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 374 $22.93 $8,575.82
Disclosure

SEC source: 0001437749-23-001487 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,167

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
January 03, 2023 Filed Jan 11, 2023 00:02 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantRestricted Stock Award · Derivative 12,450 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001437749-23-000821 · rdgdoc.xml · derivative · entry 2

Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,450

Underlying: Common Stock · 12,450 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

Read SEC document
January 03, 2023 Filed Jan 11, 2023 00:02 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantCommon Stock 12,450 Not disclosed Not disclosed
Disclosure

SEC source: 0001437749-23-000821 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,541

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2023 compensation.

Read SEC document
November 10, 2022 Filed Nov 15, 2022 01:03 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 38 $23.16 $880.08
Disclosure

SEC source: 0001437749-22-027395 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,091

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
October 28, 2022 Filed Nov 1, 2022 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 272 $21.76 $5,918.72
Disclosure

SEC source: 0001437749-22-025239 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,129

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
August 10, 2022 Filed Aug 12, 2022 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 40 $23.17 $926.80
Disclosure

SEC source: 0001437749-22-020213 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,401

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
July 22, 2022 Filed Jul 27, 2022 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleComon Stock 252 $17.85 $4,498.20
Disclosure

SEC source: 0001437749-22-017814 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,441

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
May 13, 2022 Filed May 18, 2022 00:02 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 40 $12.32 $492.80
Disclosure

SEC source: 0001437749-22-012849 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,693

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
April 21, 2022 Filed Apr 23, 2022 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 325 $13.94 $4,530.50
Disclosure

SEC source: 0001437749-22-009565 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,733

F1 · kind: The sale reported herein was made by a broker to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
February 24, 2022 Filed Mar 10, 2022 02:20 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantRestricted Stock Award · Derivative 14,019 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001437749-22-005772 · rdgdoc.xml · derivative · entry 2

Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,019

Underlying: Common Stock · 14,019 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

Read SEC document
February 24, 2022 Filed Mar 10, 2022 02:20 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantCommon Stock 14,019 Not disclosed Not disclosed
Disclosure

SEC source: 0001437749-22-005772 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,058

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2022 compensation.

Read SEC document
February 10, 2022 Filed Feb 15, 2022 01:02 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 197 $29.38 $5,787.86
Disclosure

SEC source: 0001437749-22-003345 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,039

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
January 20, 2022 Filed Jan 25, 2022 02:07 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 332 $30.24 $10,039.68
Disclosure

SEC source: 0001437749-22-001524 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,236

F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
October 20, 2021 Filed Oct 23, 2021 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 272 $42.34 $11,516.48
Disclosure

SEC source: 0001437749-21-024187 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,568

F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
July 20, 2021 Filed Jul 23, 2021 00:30 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 1,059 $45.10 $47,760.90
Disclosure

SEC source: 0001437749-21-017394 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,840

F1 · shares: The sales reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
February 08, 2021 Filed Feb 20, 2021 01:01 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantRestricted Stock Award · Derivative 2,795 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001437749-21-003516 · rdgdoc.xml · derivative · entry 2

Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,795

Underlying: Common Stock · 2,795 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

Read SEC document
February 08, 2021 Filed Feb 20, 2021 01:01 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantCommon Stock 2,795 Not disclosed Not disclosed
Disclosure

SEC source: 0001437749-21-003516 · rdgdoc.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,899

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2021 compensation.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.